インターロイキン阻害剤の市場規模、シェア、動向分析レポート：タイプ別、投与経路別、用途別、最終用途別、地域別、セグメント別予測、2025年～2030年

インターロイキン阻害剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のインターロイキン阻害剤の市場規模は、2025年から2030年にかけて17.3%のCAGRを記録し、2030年までに722億米ドルに達すると予測されています。

この背景には、後期パイプライン医薬品の上市が予定されている強力なパイプラインがあります。

この市場の治療情勢は、安全性、有効性、忍容性の面で優劣を判断するため、医薬品が直接比較試験で比較されるようになり、競合が激化しています。例えば、UCBのビメキズマブは現在、尋常性乾癬を適応症とするヒュミラ（試験名：BE SURE）、ステラーラ（BE VIVID）、コセンティクス（BE RADIANT）に対する3つの臨床試験が進行中です。

さらに、様々な臨床試験への投資の増加や、新規分子開発のための製薬企業と研究機関の戦略的提携は、インターロイキン阻害剤市場の成長に寄与する主要な要因の一つです。例えば、ジェネンテック（F.ホフマン・ラ・ロシュ社）は、巨細胞性動脈炎の治療薬アクテムラ（トシリズマブ）の開発でマサチューセッツ総合病院と共同研究を行っています。

様々な自己免疫疾患とその治療選択肢に関する消費者の意識の高まりが需要を後押しすると予想されます。例えば、アイルランド関節炎協会（Arthritis Ireland）は関節リウマチの啓発キャンペーンを開始し、さまざまな治療選択肢や早期診断の意義について一般大衆を啓蒙しています。また、欧州クローン病・潰瘍性大腸炎連合（European Federation of Crohn's &Ulcerative Colitis Association）は、炎症性腸疾患（IBD）に苦しむ患者の意識を高めるために様々な取り組みを行っています。

インターロイキン阻害剤市場レポートハイライト

• 用途別では乾癬領域が市場をリードし、2024年のシェアは37.0%。
• 2024年には、IL-23阻害剤が乾癬やIBDなどの自己免疫疾患の治療に有効であることから、27.5%の売上シェアで市場をリード。
• タイプ別では、IL-17阻害剤が予測期間中に16.1%の大幅なCAGRを記録する見込みです。
• アジア太平洋地域は、ヘルスケアインフラの充実と可処分所得の増加により、予測期間中に最も速い成長を示すと予想されます。
• IL-阻害剤は高価格であるが、有利な償還政策が手頃な価格を実現し、市場浸透を後押しすると思われます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 インターロイキン阻害剤市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析

第4章 インターロイキン阻害剤市場：タイプのビジネス分析

• タイプ別市場シェア、2024年と2030年
• タイプセグメントダッシュボード
• 市場規模と予測および動向分析、タイプ別、2018～2030年
• IL-1阻害剤
• IL-2阻害剤
• IL-5阻害剤
• IL-6阻害剤
• IL-17阻害剤
• IL-23阻害剤
• その他

第5章 インターロイキン阻害剤市場： 投与経路のビジネス分析

• 投与経路の市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模と予測および動向分析、投与経路別、2018～2030年
• 皮下（SC）
• 静脈内（IV）

第6章 インターロイキン阻害剤市場：用途のビジネス分析

• 用途市場シェア、2024年および2030年
• 用途セグメントダッシュボード
• 市場規模と予測および動向分析、用途別、2018～2030年
• 関節リウマチ
• 乾癬
• 炎症性腸疾患（IBD）
• 喘息
• その他

第7章 インターロイキン阻害剤市場：最終用途のビジネス分析

• 最終用途市場シェア、2024年および2030年
• 最終用途セグメントダッシュボード
• 市場規模と予測および動向分析、最終用途別、2018～2030年
• 病院
• 専門クリニック
• その他

第8章 インターロイキン阻害剤市場：タイプ、投与経路、用途、最終用途別の地域推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
  • 国別、2018年-2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018年-2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018年-2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018年-2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018年-2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Johnson &Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Bausch Health Companies Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global interleukin inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 4 Global interleukin inhibitors market, by drug class, 2018 - 2030 (USD Million)
• Table 5 Global interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 6 Global interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 North America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 8 North America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
• Table 9 North America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 North America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 11 North America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 U.S. interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 13 U.S. interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 U.S. interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 15 U.S. interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Canada interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 17 Canada interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Canada interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 19 Canada interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Mexico interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 21 Mexico interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 22 Mexico interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 23 Mexico interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Europe interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
• Table 25 Europe interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 26 Europe interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 Europe interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 28 Europe interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 29 UK interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 30 UK interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 UK interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 32 UK interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Germany interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 34 Germany interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 Germany interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 36 Germany interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 France interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 38 France interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 France interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 40 France interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 41 Italy interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 42 Italy interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Italy interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 44 Italy interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Denmark interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 46 Denmark interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Denmark interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 48 Denmark interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Spain interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 50 Spain interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Spain interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 52 Spain interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 Sweden interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 54 Sweden interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 55 Sweden interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 56 Sweden interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 Norway interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 58 Norway interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 59 Norway interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 60 Norway interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 66 Japan interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 67 Japan interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 Japan interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 69 Japan interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 China interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 71 China interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 China interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 73 China interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 India interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 75 India interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 India interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 77 India interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 78 Australia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 79 Australia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Australia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 81 Australia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 82 South Korea interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 83 South Korea interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 84 South Korea interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 85 South Korea interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Thailand interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 87 Thailand interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 88 Thailand interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 89 Thailand interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Latin America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
• Table 91 Latin America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 92 Latin America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 93 Latin America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 94 Latin America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 95 Brazil interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 96 Brazil interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 97 Brazil interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 98 Brazil interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 99 Argentina interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 100 Argentina interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 101 Argentina interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 102 Argentina interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 108 South Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 109 South Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 110 South Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 111 South Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 116 UAE interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 117 UAE interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 118 UAE interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 119 UAE interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 120 Kuwait interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 121 Kuwait interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
• Table 122 Kuwait interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 123 Kuwait interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Interleukin inhibitors market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Segment outlook (USD Million)
• Fig. 10 Segment outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Interleukin inhibitors market dynamics
• Fig. 13 Interleukin inhibitors market: Porter's five forces analysis
• Fig. 14 Interleukin inhibitors market: PESTLE analysis
• Fig. 15 Interleukin inhibitors market: Type segment dashboard
• Fig. 16 Interleukin inhibitors market: Type market share analysis, 2024 & 2030
• Fig. 17 IL-1 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 18 IL-2 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 19 IL-5 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 20 IL-6 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 21 IL-17 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 22 IL-23 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 23 Others market, 2018 - 2030 (USD Million)
• Fig. 24 Interleukin inhibitors market: Route of administration segment dashboard
• Fig. 25 Interleukin inhibitors market: Route of administration market share analysis, 2024 & 2030
• Fig. 26 Subcutaneous (SC) market, 2018 - 2030 (USD Million)
• Fig. 27 Intravenous (IV) market, 2018 - 2030 (USD Million)
• Fig. 28 Interleukin inhibitors market: Application segment dashboard
• Fig. 29 Interleukin inhibitors market: Application market share analysis, 2024 & 2030
• Fig. 30 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
• Fig. 31 Psoriasis market, 2018 - 2030 (USD Million)
• Fig. 32 Inflammatory bowel disease (IBD) market, 2018 - 2030 (USD Million)
• Fig. 33 Asthma market, 2018 - 2030 (USD Million)
• Fig. 34 Others market, 2018 - 2030 (USD Million)
• Fig. 35 Interleukin inhibitors market: End use segment dashboard
• Fig. 36 Interleukin inhibitors market: End use market share analysis, 2024 & 2030
• Fig. 37 Hospitals market, 2018 - 2030 (USD Million)
• Fig. 38 Specialty clinics market, 2018 - 2030 (USD Million)
• Fig. 39 Others market, 2018 - 2030 (USD Million)
• Fig. 40 Interleukin inhibitors market revenue, by region
• Fig. 41 Regional marketplace: Key takeaways
• Fig. 42 Regional marketplace: Key takeaways
• Fig. 43 North America interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 44 U.S. country dynamics
• Fig. 45 U.S. interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 46 Canada country dynamics
• Fig. 47 Canada interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 48 Mexico country dynamics
• Fig. 49 Mexico interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 50 Europe interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 51 UK country dynamics
• Fig. 52 UK interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 53 Germany country dynamics
• Fig. 54 Germany interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 55 France country dynamics
• Fig. 56 France interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 57 Italy country dynamics
• Fig. 58 Italy interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 59 Spain country dynamics
• Fig. 60 Spain interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 61 Norway country dynamics
• Fig. 62 Norway interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 63 Sweden country dynamics
• Fig. 64 Sweden interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 65 Denmark country dynamics
• Fig. 66 Denmark interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 68 Japan country dynamics
• Fig. 69 Japan interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 70 China country dynamics
• Fig. 71 China interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 72 India country dynamics
• Fig. 73 India interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 74 Australia country dynamics
• Fig. 75 Australia interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 76 South Korea country dynamics
• Fig. 77 South Korea interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 78 Thailand country dynamics
• Fig. 79 Thailand interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 80 Latin America interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 81 Brazil country dynamics
• Fig. 82 Brazil interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 83 Argentina country dynamics
• Fig. 84 Argentina interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 85 MEA interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 86 South Africa country dynamics
• Fig. 87 South Africa interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia country dynamics
• Fig. 89 Saudi Arabia interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 90 UAE country dynamics
• Fig. 91 UAE interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait country dynamics
• Fig. 93 Kuwait interleukin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 94 Company categorization
• Fig. 95 Company market position analysis
• Fig. 96 Strategic framework

Interleukin Inhibitors Market Growth & Trends:

The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB's bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Interleukin Inhibitors Market Report Highlights:

• By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
• In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
• By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
• Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
• Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Route of Administration
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Interleukin Inhibitors Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Interleukin Inhibitors Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. IL-1 Inhibitors
  • 4.4.1. IL-1 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.5. IL-2 Inhibitors
  • 4.5.1. IL-2 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. IL-5 Inhibitors
  • 4.6.1. IL-5 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.7. IL-6 Inhibitors
  • 4.7.1. IL-6 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. IL-17 Inhibitors
  • 4.8.1. IL-17 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.9. IL-23 Inhibitors
  • 4.9.1. IL-23 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Interleukin Inhibitors Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2024 & 2030
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 5.4. Subcutaneous (SC)
  • 5.4.1. Subcutaneous (SC) Market, 2018 - 2030 (USD Million)
• 5.5. Intravenous (IV)
  • 5.5.1. Intravenous (IV) Market, 2018 - 2030 (USD Million)

Chapter 6. Interleukin Inhibitors Market: Application Business Analysis

• 6.1. Application Market Share, 2024 & 2030
• 6.2. Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Rheumatoid Arthritis
  • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
• 6.5. Psoriasis
  • 6.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
• 6.6. Inflammatory Bowel Disease (IBD)
  • 6.6.1. Inflammatory Bowel Disease (IBD) Market, 2018 - 2030 (USD Million)
• 6.7. Asthma
  • 6.7.1. Asthma Market, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Interleukin Inhibitors Market: End Use Business Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. End Use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 7.5. Specialty Clinics
  • 7.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Interleukin Inhibitors Market: Regional Estimates & Trend Analysis by Type, Route of Administration, Application, and End Use

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novartis AG
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. AbbVie Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Eli Lilly and Company
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Regeneron Pharmaceuticals Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Johnson & Johnson Services, Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. F. Hoffmann-La Roche Ltd
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. AstraZeneca
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Bausch Health Companies Inc.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. GlaxoSmithKline plc
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Teva Pharmaceutical Industries Ltd
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives